ACAMBIS PLC

Acambis plc is a Biotechnology company.

#SimilarOrganizations #More

ACAMBIS PLC

Industry:
Biotechnology Health Care Therapeutics

Status:
Active


Similar Organizations

artemis-medical-logo

Artemis Medical

Artemis Medical is a Biotechnology company.

not_available_image

Icoria

Icoria is a Biotechnology company.

not_available_image

Pharmacia Biotech

Pharmacia Biotech is a Biotechnology company.

vasogen-inc-logo

Vasogen Inc

Vasogen Inc is a Biotechnology company.

More informations about "Acambis plc"

Acambis plc - Cambridge, United Kingdom - bionity.com

Feb 27, 2008 Acambis plc was formerly known as Peptide Therapeutics Group PLC and changed its name to Acambis plc in December, 2000. The company was founded in 1992 and …See details»

Acambis Company Profile 2024: Valuation, Investors, Acquisition

Peptide Therapeutics Group Plc. Ownership Status. Acquired/Merged. Financing Status. Formerly PE-Backed. Corporate Office. ... Alta Berkeley, Prelude Ventures (Cambridge), and The …See details»

Acambis plc - Crunchbase Company Profile & Funding

Alternatives and possible competitors to Acambis plc may include Subintro, Vasogen Inc, and Artemis Medical. Unlock even more features with Crunchbase Pro Start Your Free TrialSee details»

Sanofi to buy vaccine maker Acambis for $548 mln | Reuters

Jul 28, 2008 Sanofi-Aventis SA <SASY.PA> agreed on Friday to buy British vaccine maker Acambis Plc <ACM.L> for 276 million pounds ($547.8 million), in a deal highlighting big drug …See details»

Sanofi-Aventis to complete Acambis deal - Financial Times

Sep 24, 2008 Sanofi-Aventis, the French pharmaceutical group, is set to complete its acquisition of Acambis of the UK on Thursday, with plans to keep the vaccine developer partly …See details»

Acambis PLC | www.inknowvation.com

Mar 8, 2019 Previously an independent, publicly held biopharmaceutical company, in May 1999 Acambis Inc, (formerly dba as Oravax) was acquired British firm Peptide Therapeutics Group …See details»

Sanofi Pasteur Completes the Acquisition of Acambis

Sep 25, 2008 Acambis' skilled workforce of individuals who share our passion for vaccines and prevention of infectious diseases will contribute to our efforts in answering unmet medical …See details»

Acambis Plc: Drug pipelines, Patents, Clinical trials - Synapse

Explore Acambis Plc with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 20 news, and 65 literature.See details»

Acambis plc - Tech Stack, Apps, Patents & Trademarks - Crunchbase

Organization. Acambis plc . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. IT Spend by Aberdeen. Edit IT Spend by Aberdeen Section. This …See details»

PTL-16308 - Drug Targets, Indications, Patents - Synapse - Patsnap

PTL-16308: a Syk inhibitors, ZAP70 inhibitors Drug, Initially developed by Acambis Plc, Now, its global highest R&D status is Pending, Mechanism: Syk inhibitors ...See details»

Sanofi Pasteur completes Acambis vaccines takeover | Reuters

Sanofi Pasteur has completed the 285 million pound ($530 million) takeover of vaccines maker Acambis Plc, the vaccines division of French drugmaker Sanofi-Aventis <SASY.PA> said on …See details»

Acambis smallpox contract timeline slips back | Reuters

British vaccine maker Acambis Plc &lt;ACM.L&gt; said on Thursday it hoped to finalise an exclusive agreement with the U.S. government to supply smallpox vaccines by early next year. …See details»

Sanofi-Aventis to buy Acambis for about $549.5 mln

SAN FRANCISCO (MarketWatch) -- Sanofi Pasteur Holding, a vaccines division of Sanofi-Aventis , will buy United Kingdom's Acambis PLC for a total of about 276...See details»

Acambis shares soar on $548M buyout deal - Fierce Biotech

Jul 28, 2008 Shares of Acambis PLC soared after Sanofi-Aventis announced that it planned to buy the vaccine developer for $548 million. Aside from the smallpox vaccine ACAM2000, …See details»

PTL-11031 - Drug Targets, Indications, Patents - Synapse

PTL-11031: a Protease inhibitors, Viral protease modulators Drug, Initially developed by Acambis Plc, Now, its global highest R&D status is Pending, Mechanism: Protease inhibitors,Viral …See details»

Sanofi to acquire Acambis for $546M - Fierce Biotech

Jul 25, 2008 More evidence that the vaccine market is hot: vaccine maker Acambis has agreed to a £276 million ($546 million) by Sanofi-Pasteur, the vaccines division of France's Sanofi …See details»

TRANSFORMATION OF ACAMBIS - UCLA Fielding School of Public …

Apr 16, 2003 Transformation of Acambis. Smallpox pact frees firm from cash concerns. By Naomi Aoki, Globe Staff. CAMBRIDGE -- Acambis PLC is a rarity in the biotech industry: It …See details»

Sanofi makes $548M deal for Acambis - Fierce Pharma

Jul 28, 2008 Sanofi Pasteur has inked a deal to buy vaccine-maker Acambis for about $548 million (£276 million), a 64 percent per-share premium. The two companies had already been …See details»

Sanofi Pasteur and Acambis join forces to bring West Nile vaccine …

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive global collaboration agreement with Acambis plc, for the development and …See details»

linkstock.net © 2022. All rights reserved